Drug Trial Radar · NCT05416307
Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
156
Planned (sponsor's estimate)
Start
May 19, 2022
Primary completion
Mar 2028
Study completion Mar 2030
Sponsor
- Lead sponsor
- Electra Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. Secondary hemophagocytic lymphohistiocytosis (sHLH) is the most common form of this disease and is typically associated with several other clinical conditions (eg, malignancy associated HLH (mHLH), infection, or autoimmune disease). ELA026 is a fully human immunoglobulin G1 (IgG1) signal regulatory protein (SIRP)-directed monoclonal antibody designed to deplete the myeloid and T cells driving the inflammation. The purpose of this study is to assess the safety, efficacy pharmacokinetics and pharmacodynamics of ELA026 in participants with sHLH.
Conditions
- Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Interventions
ELA026Drug
Multiple doses of ELA026
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participant with Incidence of Treatment-Emergent Adverse Events (TEAEs) [Safety and tolerability]Time frame: Up to Week 12
- Part 2 (Cohort A): 56-day Survival Rate in Participants with mHLH and Have Lymphoma as the Cancer TriggerTime frame: 56 days
Locations
42 sites in 7 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham School of Medicine
Birmingham, Alabama · Recruiting
Phoenix Children's Hospital
Phoenix, Arizona · Completed
University of California, Los Angeles
Los Angeles, California · Completed
MedStar Georgetown University Hospital
Washington D.C., District of Columbia · Recruiting
Johns Hopkins All Children's Hospital
St. Petersburg, Florida · Recruiting
Children's Healthcare of Atlanta - Center for Advanced Pediatrics
Atlanta, Georgia · Recruiting
Emory University
Atlanta, Georgia · Recruiting
National Institute of Allergy and Infectious Diseases (NIAID)
Rockville, Maryland · Recruiting
Columbia University
New York, New York · Recruiting
Cornell University
New York, New York · Recruiting
Hackensack University Medical Center
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Cleveland Clinic Main Campus
Cleveland, Ohio · Recruiting
Thomas Jefferson University
Philadelphia, Pennsylvania · Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas · Recruiting
Texas Children's Hospital
Houston, Texas · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Huntsman Cancer Institute
Salt Lake City, Utah · Recruiting
Fred Hutchinson Cancer Center - Seattle Cancer Care Alliance (SCCA) Location
Seattle, Washington · Recruiting
Medizinische Universität Innsbruck
Innsbruck, Austria · Withdrawn
Medical University of Vienna
Vienna, Austria · Completed
Schwarzwald-Baar Klinikum Villingen-Schwenningen
Villingen-Schwenningen, Germany · Recruiting
Universitätsklinikum Jena
Jena, Thuringia, Germany · Recruiting
Azienda Ospedaliero Universitaria Meyer
Florence, Italy · Recruiting
IRCCS Istituto Giannina Gaslini
Genova, Italy · Recruiting
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Milan, Italy · Completed
Fondazione IRCCS San Gerardo dei Tintori (Ospedale San Gerardo)
Monza, Italy · Recruiting
Azienda Ospedale Università di Padova
Padova, Italy · Recruiting
Bambino Gesu' Roma
Roma, Italy · Withdrawn
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Materno-Infantile Burlo Garofolo
Trieste, Italy · Recruiting
Radboud Universitair Medisch Centrum
Nijmegen, Netherlands · Recruiting
Erasmus UMC
Rotterdam, Netherlands · Active not recruiting
Wilhelmina Kinderziekenhuis
Utrecht, Netherlands · Recruiting
Amsterdam Universitair Medische Centra - Locatie Academisch Medisch Centrum
Amsterdam, Noord-Holland - NET, Netherlands · Recruiting
Hospital 12 de Octubre, Madrid
Madrid, Spain · Withdrawn
Hospital Ramon y Cajal
Madrid, Spain · Completed
Hospital La Fe Valencia
Valencia, Spain · Withdrawn
Clinica Universidad de Navarra - Madrid
Madrid, Madrid - SPA, Spain · Recruiting
Clinica Universidad de Navarra - Pamplona
Pamplona, Navarre - SPA, Spain · Recruiting
Hospital Universitario Virgen del Rocio
Seville, Sevilla - SPA, Spain · Recruiting
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.